Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 4/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003034 | 0.82 | PSMB5 (0.48) | BACE1ANPEPRENPSMB5 | |
| SCHEMBL5500141 | 0.77 | EPHX1 (0.47) | BACE1 | |
| SCHEMBL30442889 | 0.74 | CACNA2D1 (0.44) | CTSD | |
| SCHEMBL31692789 | 0.73 | CACNA2D1 (0.40) | CTSD | |
| SCHEMBL29885722 | 0.72 | CACNA2D1 (0.42) | CTSD | |
| SCHEMBL609044 | 0.71 | KDM4E (0.36) | HPGDBACE1ANPEPRENPSMB5 | |
| SCHEMBL27773780 | 0.71 | KDM4E (0.36) | HPGDBACE1ANPEPRENPSMB5 | |
| SCHEMBL30395496 | 0.71 | CACNA2D1 (0.41) | CTSDPSMB5 | |
| SCHEMBL13995948 | 0.71 | ALDH1A1 (0.53) | HPGDANPEP | |
| SCHEMBL13995890 | 0.71 | ALDH1A1 (0.53) | HPGDANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276484-B2 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | ELAN PHARMACEUTICALS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-6864240-B1 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | BACE1, APP, BACE2 | HPGD 3102/4885CTSD 92/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.